Trial Profile

An ALLG Phase II study of pembrolizumab checkpoint blockade following chemoimmunotherapy for primary central nervous system lymphoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Cytarabine; Methotrexate; Procarbazine; Rituximab; Thiotepa; Vincristine
Indications CNS cancer; Diffuse large B cell lymphoma; Lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; Therapeutic Use
Acronyms BLOCK PCNSL

Most Recent Events

10 Dec 2024 Status changed from not yet recruiting to recruiting.
10 Dec 2024 Trial design presented at the 66th American Society of Hematology Annual Meeting and Exposition
26 Feb 2020 Planned initiation date changed from 1 Oct 2019 to 1 Jun 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com